FDA’s oncology advisory committee to consider MRD as a multiple myeloma endpoint


Yesterday, the FDA announced that its Oncologic Drugs Advisory Committee would weigh in on the potential use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials.

Cancers of the blood and bone marrow can affect production and function of white blood cells, red blood cells, and platelets, all produced by hematopoietic stem cells.

Fill out the form to read the full article.

Required *

Copy link
Powered by Social Snap